Management of Breakthrough Seizure in Patients Receiving Phenytoin

Immediate Diagnostic Steps

• Obtain a stat serum phenytoin concentration to differentiate inadequate dosing, non‑adherence, or toxicity as the cause of a breakthrough seizure. 1
• Therapeutic total phenytoin concentration is 10–20 µg/mL (free 1–2 µg/mL); some individuals require levels > 15 µg/mL for optimal seizure control. 2
• Perform emergent brain imaging (CT or MRI) to rule out acute structural lesions, hemorrhage, tumor progression, or other intracranial pathology that could precipitate increased seizure frequency. 1

Management Algorithm Based on Phenytoin Level

Sub‑therapeutic Level (< 10 µg/mL)

• Administer an intravenous loading dose of 18–20 mg/kg (maximum infusion rate 50 mg/min) to rapidly achieve therapeutic concentrations. 2
• Alternatively, use fosphenytoin at 150 PE/min (approximately three times faster than phenytoin) which is associated with fewer adverse events. 2
• Increase the maintenance dose by 100–200 mg/day at weekly intervals, monitoring efficacy and toxicity, with a typical adult maximum of 1200 mg/day. 2

Therapeutic Level (10–20 µg/mL)

• Recognize that a subset of patients may need concentrations > 15 µg/mL to maintain seizure control; consider this before escalating dose. 2
• Add a second antiepileptic agent rather than pushing phenytoin into toxic ranges. 3
• Valproate provides superior seizure control for primary generalized tonic‑clonic seizures compared with phenytoin (66 % vs 42 % control; number needed to treat = 4.3). 3

Supratherapeutic Level (> 20 µg/mL)

• Hold phenytoin immediately; initiate an alternative anticonvulsant (e.g., levetiracetam) while the phenytoin level declines. 2
• Monitor for classic signs of phenytoin toxicity such as nystagmus, ataxia, dizziness, and cognitive changes. 2

Status Epilepticus Considerations

• In status epilepticus, lorazepam is more effective than phenytoin alone (65 % vs 44 % success). 3
• For benzodiazepine‑refractory status, intravenous valproate 30 mg/kg achieves higher seizure control than phenytoin 18 mg/kg (66 % vs 42 %). 3
• High‑dose phenytoin (mean 23.8 mg/kg) succeeds in only 38 % of refractory status epilepticus cases. 4

Post‑Intervention Monitoring

• Re‑measure the phenytoin level 2–4 hours after an intravenous loading dose to confirm attainment of the therapeutic range. 2
• Approximately 50 % of patients exhibit sub‑therapeutic concentrations at 12 hours post‑loading, underscoring the need for this monitoring point. 2
• Observe for dose‑related adverse effects, including ataxia, nystagmus, tremor, somnolence, and cognitive impairment. 2

Management of Supratherapeutic Phenytoin Levels

Clinical Signs of Phenytoin Toxicity

• In patients with phenytoin concentrations markedly above the therapeutic range (e.g., >30 µg/mL), ataxia and gait disturbance are common neurologic manifestations of toxicity. 5
• Somnolence and altered mental status frequently accompany supratherapeutic phenytoin levels and may herald impending encephalopathy. 5

Bridging Anticonvulsant Therapy

• Levetiracetam can be administered as an immediate bridge (loading dose ≈ 1,500 mg orally or intravenously) to maintain seizure control while phenytoin levels decline. 5
• In clinical studies, no seizures were observed within the first 24 hours after levetiracetam loading, indicating effective seizure prophylaxis during the transition. 5
• Reported adverse effects of levetiracetam loading are generally mild, most commonly fatigue and dizziness. 5

Alternative Anticonvulsant Options

• Intravenous valproate at 30 mg/kg, infused at a maximum rate of 10 mg/kg/min, is considered safe and well‑tolerated for patients requiring an alternative to phenytoin. 5